Antibiotics — Mechanisms and Clinical Use

• Cell wall inhibition: Beta-lactams (penicillins, cephalosporins, carbapenems) and glycopeptides inhibit peptidoglycan cross-linking by binding penicillin-binding proteins (PBPs), preventing cell wall synthesis. This leads to osmotic instability and bacterial lysis, making them bactericidal. Resistance occurs via beta-lactamase production (enzymatic degradation) or PBP alterations.

• Protein synthesis inhibition: Aminoglycosides (irreversible 30S ribosomal binding), tetracyclines (reversible 30S binding), macrolides (50S binding), and chloramphenicol (50S binding) interfere with bacterial translation. Aminoglycosides are bactericidal (cause ribosomal misreading), while others are typically bacteriostatic (block new protein synthesis).

• DNA/RNA synthesis inhibition: Fluoroquinolones inhibit DNA gyrase and topoisomerase IV, preventing DNA replication and transcription (bactericidal). Rifampin inhibits bacterial RNA polymerase. These agents are highly effective for intracellular organisms.

• Folate metabolism antagonism: Sulfonamides and trimethoprim block sequential steps in bacterial folate synthesis required for nucleotide production (bacteriostatic). Often used in combination (trimethoprim-sulfamethoxazole; TMP-SMX) for synergistic effect.

• Cell membrane disruption: Polymyxins (polymyxin B, colistin) bind lipopolysaccharides on gram-negative bacteria, disrupting the outer membrane (bactericidal). Reserved for multidrug-resistant organisms due to nephrotoxicity and neurotoxicity.

• Community-acquired bacterial infections: Respiratory tract infections (pneumonia, sinusitis, otitis media), urinary tract infections (cystitis, pyelonephritis), skin and soft tissue infections, and gastroenteritis require tailored antibiotic selection based on likely pathogens and local epidemiology.

• Sepsis presentations: Fever, tachycardia, tachypnea, hypotension, and altered mental status in the setting of suspected infection demand rapid empiric broad-spectrum antibiotic coverage; early recognition and administration within 1 hour improves mortality significantly.

• Site-specific considerations: CNS infections require agents with good blood-brain barrier penetration (ceftriaxone, vancomycin); respiratory infections favor agents concentrating in lung tissue (fluoroquinolones, macrolides); endocarditis requires bactericidal agents with high-dose, prolonged therapy.

• Clinical pearls: The presence of fever with localizing signs (dysuria with pyuria, productive cough with infiltrate, purulent drainage) supports bacterial infection and may warrant antibiotics, though viral infections are common. De-escalation after culture results and sensitivity testing is standard practice to reduce resistance.

• Culture and sensitivity testing: Blood, urine, cerebrospinal fluid, wound, or respiratory secretions should be cultured before antibiotic initiation when possible. Gram stain provides rapid preliminary identification (gram-positive cocci in clusters = Staphylococcus, chains = Streptococcus; gram-negative rods = Escherichia coli, Pseudomonas). Sensitivity patterns guide definitive therapy and identify resistance mechanisms (ESBL, methicillin-resistance, VRE).

• Imaging and clinical assessment: Chest X-ray for pneumonia, urinalysis with culture for UTI, wound assessment for soft tissue infection. Procalcitonin and C-reactive protein support bacterial infection diagnosis but are nonspecific; lactate elevation and band predominance on CBC suggest systemic infection.

• Diagnostic criteria by syndrome: Pneumonia requires compatible clinical symptoms plus infiltrate on imaging; UTI requires pyuria plus ≥10^5 CFU/mL in symptomatic patients; cellulitis is primarily clinical (erythema, warmth, edema without purulence); abscesses require imaging (ultrasound, CT) for identification and often drainage.

• Important diagnostic consideration: Empiric broad-spectrum coverage should be initiated in sepsis while awaiting culture results; narrowing the spectrum once sensitivities return reduces resistance development and antibiotic toxicity.

• Empiric therapy for common syndromes:
• Community-acquired pneumonia (CAP): Outpatient = amoxicillin or doxycycline; hospitalized = ceftriaxone ± azithromycin; ICU/severe = ceftriaxone + vancomycin ± fluoroquinolone (covers Streptococcus pneumoniae, Haemophilus influenzae, atypicals)
• Uncomplicated UTI: Nitrofurantoin 100 mg BID × 5–7 days or TMP-SMX DS BID × 3 days (first-line)
• Cellulitis: Cephalexin 500 mg QID (oral) or ceftriaxone 1 g IV Q8H (covers Staphylococcus aureus, Streptococcus pyogenes); add vancomycin if MRSA risk
• Sepsis: Broad-spectrum coverage: piperacillin-tazobactam 4.5 g IV Q6H OR ceftriaxone + vancomycin ± fluoroquinolone (pending cultures)

• Definitive therapy post-culture:
• Penicillin-susceptible pneumococcus: Penicillin G 2–4 MU IV Q4H OR ceftriaxone (meningitis requires higher doses)
• MRSA: Vancomycin 15–20 mg/kg IV Q8–12H (AUC-guided dosing, AUC/MIC 400-600 per the 2020 IDSA/ASHP consensus; trough-only targets are no longer recommended) OR doxycycline OR clindamycin (if susceptible)
• Pseudomonas aeruginosa: Antipseudomonal beta-lactam (piperacillin-tazobactam, cefepime, meropenem) ± aminoglycoside or fluoroquinolone
• Enterococcus: Ampicillin or penicillin (vancomycin if ampicillin-resistant)

• Special populations:
• Pregnancy: Avoid fluoroquinolones (tendon rupture risk, effects on fetal cartilage), tetracyclines (tooth discoloration), trimethoprim (1st trimester = neural tube defects). Safe options: penicillins, cephalosporins, nitrofurantoin (except near term), macrolides.
• Renal impairment: Aminoglycosides and vancomycin require dose adjustment based on creatinine clearance. Fluoroquinolones, beta-lactams, and macrolides have minimal renal excretion.
• Hepatic impairment: Macrolides, fluoroquinolones, and rifampin require caution; prefer renally eliminated agents (beta-lactams, aminoglycosides).
• Drug interactions: Fluoroquinolones chelate divalent cations (separate dosing from antacids, iron, zinc); macrolides inhibit CYP3A4 (increased warfarin, statins, the

Beta-lactams

• Hypersensitivity: IgE-mediated anaphylaxis is the feared reaction; a benign delayed morbilliform rash does not predict IgE-mediated anaphylaxis and can be evaluated for delabeling, but severe delayed T-cell–mediated reactions (SJS/TEN, DRESS, AGEP) preclude re-challenge entirely and are a contraindication to skin testing/oral challenge. Cross-reactivity between penicillins and cephalosporins is roughly 1–3% and tracks with shared R1 side chains, not the beta-lactam ring — the historical 10% figure is obsolete. The AAAAI/ACAAI drug allergy practice parameter supports skin testing and oral challenge to delabel reported penicillin allergy.
• Neurotoxicity: high-dose penicillins and cefepime antagonize GABA-A, causing myoclonus, encephalopathy, and seizures — classically in renal impairment where dose reduction was omitted.
• Other: acute interstitial nephritis (eosinophiluria, WBC casts), Clostridioides difficile colitis, ceftriaxone biliary sludging and kernicterus in neonates (bilirubin displacement; never co-administer with IV calcium in neonates), and NMTT-side-chain agents (cefotetan) causing hypoprothrombinemia (reverse with vitamin K) and disulfiram-like reactions.

Requiring active monitoring

• Vancomycin: nephrotoxicity, amplified when combined with piperacillin-tazobactam. Dose to a 24-hour AUC with AUC/MIC 400–600 per the 2020 IDSA/ASHP consensus. Vancomycin flushing syndrome is direct mast-cell histamine release, not IgE — treat with slower infusion and antihistamine.
• Aminoglycosides: proximal tubular ATN (non-oliguric, reversible) and irreversible ototoxicity/vestibulotoxicity from cochlear hair-cell destruction; also neuromuscular blockade (blocks presynaptic ACh release) — avoid in myasthenia gravis; IV calcium is the reversal. Teratogenic (fetal ototoxicity).
• Linezolid: reversible myelosuppression and serotonin syndrome (weak MAO inhibition). Daptomycin: myopathy — follow CK.

Class-specific toxicities

• Fluoroquinolones: FDA boxed warnings for tendinopathy/*Achilles rupture*, peripheral neuropathy, CNS effects, and myasthenia exacerbation; also QT prolongation, dysglycemia, and association with aortic aneurysm/dissection.
• Macrolides: QT prolongation, CYP3A4 inhibition (erythromycin/clarithromycin), motilin-agonist GI cramping, and infantile hypertrophic pyloric stenosis.
• TMP-SMX: SJS/TEN, hyperkalemia (trimethoprim blocks ENaC), creatinine rise without true GFR loss, hemolysis in G6PD deficiency, and megaloblastic anemia — rescued with leucovorin.

• Vancomycin monitoring: the answer is AUC-guided dosing with AUC/MIC 400–600 (2020 IDSA/ASHP/PIDS/SIDP consensus). A trough-only goal of 15–20 mcg/mL is the retired target and is the classic distractor; current practice is 24-hour AUC-guided dosing.
• "Red man" is not an allergy: flushing over the face and torso during a rapid infusion is histamine release. Slow the infusion and pretreat with an antihistamine — do not relabel the patient as vancomycin-allergic or switch agents.
• Penicillin allergy stems: a remote maculopapular rash is not a contraindication to cephalosporins. Cross-reactivity is ~1–3% and driven by shared R1 side chains; cefazolin has a unique side chain and is generally tolerated. Best next step in an elective setting is allergy evaluation/delabeling, not lifelong vancomycin.
• Aminoglycosides fail in abscesses: uptake across the bacterial membrane is oxygen-dependent, so they are inactive against anaerobes and in acidic, hypoxic pus. Their concentration-dependent killing plus post-antibiotic effect is why once-daily dosing is used.
• Achilles tendon rupture in an older patient on a steroid + a new antibiotic = fluoroquinolone. Same class: avoid in myasthenia gravis, and separate dosing from antacids, iron, calcium, and zinc (chelation destroys bioavailability).
• The D-test: erythromycin-resistant, clindamycin-susceptible S. aureus must be tested for inducible erm-mediated resistance before clindamycin is used — a flattened zone ("D" shape) means treatment failure.
• Ceftriaxone has no antipseudomonal activity. If the stem features neutropenic fever, ventilator-associated pneumonia, or burns, the answer is cefepime, ceftazidime, piperacillin-tazobactam, or a carbapenem.
• Sepsis timing: draw blood cultures first, then treat. Septic shock or high-probability sepsis → antibiotics within 1 hour of recognition. Possible sepsis without shock → Surviving Sepsis Campaign 2021 permits up to 3 hours for rapid diagnostic evaluation before empiric therapy. De-escalate once sensitivities return.
• TMP-SMX creatinine bump: trimethoprim blocks tubular creatinine secretion. A modest rise without oliguria or urinary abnormalities is not acute kidney injury.